1. Generics Bulletin
  2. >>Products

Irish Body Calls For Urgent Action To Tackle Drug Shortages

The Statement Doubles Down On The Group’s Recent Manifesto

 
• By Adam Zamecnik

Medicines for Ireland has called for action that would alleviate drug shortages affecting every fifth patient in the country after recently urging strategic reform in the EU.

Irish flag
• Source: Shutterstock

The generic industry representative body Medicines for Ireland has called for urgent action to tackle the growing issue of drug shortages in the country.

Citing a recent Red C survey, Medicines for Ireland highlighted that 20% of Irish patients have been personally affected by medical shortages in the past two years

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

Amneal Proud To Be ‘Made In America’ And Ready To Scale Up Its US Manufacturing

 
• By Urtė Fultinavičiūtė

Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.

‘I’ll Be Happy When We Have 40-Plus Assets’ – Sandoz Builds Up Biosimilars

 
• By Dave Wallace

With biosimilars playing an increasingly important role in Sandoz’s business, the firm’s first-quarter results call saw management lay out the latest key developments. Meanwhile, the company also addressed the issue of US tariffs, voicing optimism over both future developments as well as its ability to weather current measures.

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.